Terms: = Colorectal cancer AND PBX1, P40424, 5087
4 results:
1. Clinicopathological utility of miR-203a-3p in diagnosing colorectal cancer.
Qasemi Rad M; Pouresmaeil V; Hosseini Mojahed F; Amirabadi A; Aalami AH
Mol Biol Rep; 2022 Jul; 49(7):6975-6985. PubMed ID: 35511316
[TBL] [Abstract] [Full Text] [Related]
2. Diagnosing deficits in quality of life and providing tailored therapeutic options: Results of a randomised trial in 220 patients with colorectal cancer.
Klinkhammer-Schalke M; Steinger B; Koller M; Zeman F; Fürst A; Gumpp J; Obermaier R; Piso P; Lindberg-Scharf P;
Eur J Cancer; 2020 May; 130():102-113. PubMed ID: 32179445
[TBL] [Abstract] [Full Text] [Related]
3. HOXB7 and Hsa-miR-222 as the Potential Therapeutic Candidates for Metastatic colorectal cancer.
Iman M; Mostafavi SS; Arab SS; Azimzadeh S; Poorebrahim M
Recent Pat Anticancer Drug Discov; 2016; 11(4):434-443. PubMed ID: 27855613
[TBL] [Abstract] [Full Text] [Related]
4. Metabolic syndrome and colorectal neoplasms: An ominous association.
Trabulo D; Ribeiro S; Martins C; Teixeira C; Cardoso C; Mangualde J; Freire R; Gamito É; Alves AL; Augusto F; Oliveira AP; Cremers I
World J Gastroenterol; 2015 May; 21(17):5320-7. PubMed ID: 25954106
[TBL] [Abstract] [Full Text] [Related]
